8-K: Clearside Biomedical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical announced its second quarter 2024 financial results, highlighting the progress of its Phase 2b ODYSSEY trial and other corporate developments.

Summary

• Clearside Biomedical reported a net loss of $7.6 million, or $0.10 per share, for the second quarter of 2024, compared to a net loss of $9.1 million, or $0.15 per share, for the same period in 2023.
• License and other revenue for the quarter was $90,000, a decrease from $1.0 million in the second quarter of 2023.
• Research and development expenses decreased to $4.6 million from $4.9 million in the prior year's quarter.
• The company's cash, cash equivalents, and short-term investments totaled $29.4 million as of June 30, 2024.
• Clearside believes it has sufficient resources to fund operations into the third quarter of 2025.
• The Phase 2b ODYSSEY trial for CLS-AX in wet AMD is on track, with topline data expected in late Q3 2024.
• The Safety Review Committee recommended the ODYSSEY trial continue as planned, with no drug-related serious adverse events observed.
• Clearside's partner, Arctic Vision, reported positive results from their Phase 3 trial for XIPERE in China and has submitted new drug applications in Australia and Singapore.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and partnerships, although financial results show a loss. The company's cash runway is also a positive factor.

Positives

• The Phase 2b ODYSSEY trial is on track with topline data expected in late Q3 2024.
• No drug-related serious adverse events were observed in the ODYSSEY trial.
• Arctic Vision's positive Phase 3 results and NDA submissions for ARCATUS are significant milestones.
• Real-world data for XIPERE shows excellent durability, with most patients not needing additional treatment for 6 months.
• The publication of consensus guidelines for suprachoroidal drug delivery validates Clearside's technology.
• REGENXBIO's progress with their suprachoroidal delivery programs is a positive development for Clearside's platform.
• The company's net loss decreased compared to the same quarter last year.
• Clearside has sufficient resources to fund operations into the third quarter of 2025.

Negatives

• License and other revenue decreased significantly to $90,000 from $1.0 million in the second quarter of 2023.
• The company reported a net loss of $7.6 million for the quarter.
• Research and development expenses decreased slightly, which could indicate a slowdown in some areas of development.

Risks

• The company is reliant on the success of its clinical trials, particularly the Phase 2b ODYSSEY trial.
• Clearside depends on third-party partners for commercialization and development of its products.
• The company's financial performance is subject to fluctuations in revenue and expenses.
• There are inherent risks and uncertainties in the development of new pharmaceutical products.
• The company's ability to fund operations is dependent on maintaining sufficient cash reserves.

Future Outlook

Clearside believes it has sufficient resources to fund its planned operations into the third quarter of 2025. Topline data from the Phase 2b ODYSSEY trial is expected in late Q3 2024.

Management Comments

• George Lasezkay, PharmD, JD, President and Chief Executive Officer, stated that the Phase 2b ODYSSEY clinical trial is on track and on time with topline data expected in late Q3 2024.
• Dr. Lasezkay highlighted the importance of re-dosing with CLS-AX in the ODYSSEY trial and its value for future clinical development.
• Dr. Lasezkay emphasized the advantages of suprachoroidal administration using Clearside's proprietary SCS Microinjector.

Industry Context

The announcement highlights the growing interest in suprachoroidal drug delivery as a method for treating retinal diseases. The positive results from Arctic Vision's Phase 3 trial and the publication of consensus guidelines underscore the potential of this approach. Clearside's partnerships and clinical trial progress position them as a key player in this space.

Comparison to Industry Standards

• Clearside's focus on suprachoroidal drug delivery is a differentiating factor compared to traditional intravitreal injections used by companies like Regeneron (Eylea) and Roche (Lucentis).
• The reported 87.7% durability of XIPERE is notable, as many current treatments for macular edema require frequent injections.
• REGENXBIO's progress with their gene therapy programs using Clearside's delivery platform is comparable to other companies exploring gene therapy for retinal diseases, such as Adverum Biotechnologies and Biogen.
• The publication of consensus guidelines for suprachoroidal injection is a significant step towards standardizing the procedure, similar to the development of best practices for intravitreal injections.

Management Changes

Stakeholder Impact

• Shareholders may view the progress in clinical trials and partnerships positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with retinal diseases may benefit from the development of new treatments.
• Partners may be encouraged by the positive results and progress of Clearside's technology.

Next Steps

• Clearside will continue to advance the Phase 2b ODYSSEY clinical trial.
• The company anticipates topline data from the ODYSSEY trial in late Q3 2024.
• Clearside will continue to support its partners in the commercialization of XIPERE.
• The company will resume quarterly earnings conference calls with the third quarter 2024 financial results.

Key Dates

Keywords

suprachoroidal, drug delivery, wet AMD, CLS-AX, XIPERE, ODYSSEY trial, retinal diseases, ophthalmology, Arctic Vision, REGENXBIO